Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of filgotinib in ulcerative colitis
MOH_2017-05-22_000450Phase 3Recruiting
- Sponsor
- Alfasigma
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of filgotinib in autoimmune colitis (3 arms), sponsored by Alfasigma. Started Apr 2017; status: recruiting.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-05-22_000450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-22_000450.